A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology

The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

reMYND signs the Statement in support of animal research and a transparent approach

Press release | reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.

reMYND to present on Biotechdag

Press release | VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide. 

Measuring cognition in reMYND’s Tau animal models

reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age and a strong correlation of Tau pathology with the motor phenotype.

IWT supports reMYND in developing a cure for Type 1 Diabetes

Press release | reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).